Miquel Vila Bover I am an ICREA Professor and I lead the Research Group on Neurodegenerative Diseases at the Vall d'Hebron Research Institute (VHIR) Instituciones de las que forman parte Jefe de grupo Enfermedades Neurodegenerativas Vall Hebron Institut de Recerca Miquel Vila Bover Instituciones de las que forman parte Jefe de grupo Enfermedades Neurodegenerativas Vall Hebron Institut de Recerca I am an ICREA Professor and I lead the Research Group on Neurodegenerative Diseases at the Vall d'Hebron Research Institute (VHIR)
I have a degree in Medicine and Surgery from the University of Barcelona (1993) and a PhD in Neuroscience from the University of Paris 6 (1998). My doctoral work carried out in the laboratory of experimental neurology at the Salpetriere Hospital in Paris (1993-98) contributed to establishing the subthalamic nucleus as the main therapeutic target for the surgical treatment of Parkinson's disease with deep brain stimulation. From 1998 to 2005 I worked at the Movement Disorders Unit of Columbia University in New York (USA), initially as a postdoctoral researcher and from 2001 as an Assistant Professor of Neurology, focusing on the study of the mechanisms of neuronal death in Parkinson's disease to identify new therapeutic targets for this currently incurable neurodegenerative disorder. In 2006 I moved to Barcelona as a Professor at ICREA (Catalan Institute of Research and Advanced Studies) to create and lead a new research group in neurodegenerative diseases at the Vall d'Hebron Research Institute (VHIR). Our group is now part of the Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED) and the Aligning Science Across Parkinson's Collaborative Research Network (ASAP-CRN). I am also an Associate Professor at the Autonomous University of Barcelona, Principal Investigator at CIBERNED, Coordinating Lead PI at ASAP-CRN and member of the Steering Committees of the World Parkinson Coalition and the Basic Science Special Interest Group of the International Parkinson and Movement Disorder Society.
Líneas de investigación Identification of biomarkers of prodromal Parkinson's disease Despite intensive efforts towards understanding the aetiology/pathogenesis of Parkinson's disease (PD) and the development of novel therapeutic approaches for this neurodegenerative condition, the current treatment for PD remains symptomatic and yet far from modifying disease onset or progression. Before the manifestation of the classical motor symptoms, PD patients present with non-motor symptoms in a prodromal phase. The identification of deregulated molecular pathways or genes in peripheral blood and/or cerebrospinal fluid from these prodromal patients may help develop potential biomarkers for the early detection, diagnosis, risk assessment and/or progression of PD, which are currently lacking, as well as to stratify patients at very early stages to apply more specific, personalized disease-modifying treatments. IP: Miquel Vila Bover, Ariadna Laguna Tuset Regeneration of dopaminergic neurons in Parkinson's disease via cell fusion-mediated reprogramming Co-PI: Pia Cosma, CRG. Given the current lack of disease-modifying therapies for Parkinson’s disease (PD), we are exploring whether cell-fusion-mediated regeneration of dopaminergic neurons can be achieved, for therapeutic purposes, in experimental animal models of PD after transplantation of Wnt-activated haematopoietic stem and progenitor cells (HSPCs). IP: Miquel Vila Bover Paginación Primera página « Página anterior ‹ Página 1 Página actual 2 Proyectos MECANISMOS MOLECULARES DE NEURODEGENERACION LIGADA A LA NEUROMELANINA EN LA ENFERMEDAD DE PARKINSON Y ENVEJECIMIENTO CEREBRAL IP: Miquel Vila Bover Colaboradores: Gerard Roch Alba, Miriam Izquierdo Sans Entidad financiadora: Ministerio de Ciencia e Innovación-MICINN Financiación: 99260 Referencia: PRE2021-098300 Duración: 01/07/2022 - 30/06/2026 Activity and connectivity drive neuronal vulnerability and disease progression in Parkinson's disease IP: Miquel Vila Bover Colaboradores: Activity and connectivity drive neuronal vulnerability and disease progression in Parkinson's disease, Javier Hoyo Pérez, Gerard Roch Alba, Marta González Sepúlveda, Ariadna Laguna Tuset, Joana Margalida Cladera Sastre Entidad financiadora: Michael J. Fox Foundation Financiación: 1936109 Referencia: ASAP_MJFF2021 Duración: 01/11/2021 - 31/10/2025 Characterization of the CD8 T cell response in Parkinson’s disease for the development of preventive and therapeutic strategies that halt the progression of the disease: SARS-Cov-2-induced long term-hyposmia as a possible prodromal stage IP: Jordi Bove Badell Colaboradores: Miquel Vila Bover, Alejandro Ferré Masó, Oriol de Fabregues-Boixar Nebot, Carles Lorenzo Bosquet, Antonio Palasi Franco, Maria Sellés Altés Entidad financiadora: Instituto de Salud Carlos III Financiación: 165770 Referencia: PI21/01358 Duración: 01/01/2022 - 30/06/2026 The brain-body axis in Parkinson’s disease patients: from pathophysiology to biomarkers and therapeutic approaches IP: Ariadna Laguna Tuset Colaboradores: Maria Victoria Gonzalez Martinez, Miquel Vila Bover, Daniela Samaniego Toro, The brain-body axis in Parkinson’s disease patients: from pathophysiology to biomarkers and therapeutic approaches , Sara Belmonte Calderon Entidad financiadora: Instituto de Salud Carlos III Financiación: 171820 Referencia: PI21/01603 Duración: 01/01/2022 - 30/06/2026 Paginación Primera página « Página anterior ‹ Página 1 Página actual 2 Página 3 Página 4 Página 5 … Siguiente página › Última página »
